Lundbeck announced that new data across its neurology portfolio will be presented at the American Academy of Neurology (AAN) Annual Meeting 2026, taking place April 18–22 in Chicago,… read more.
A new blood test, using a marker for late-stage Alzheimer’s disease, could offer a clinically relevant dementia diagnosis with fewer false positives, according to researchers at Lund University… read more.
In 2023, globally 259,000 people died from meningitis and 2.5 million people were infected with the disease, suggests a study published in The Lancet Neurology. Although death and infection rates have declined significantly… read more.
Older adults who develop delirium during a hospital admission face a substantially higher risk of dementia in later years, even if they had no prior health conditions, according… read more.
A new study reveals that family caregivers of Alzheimer’s patients in Oman face significant unmet needs, ranging from limited knowledge about the disease to high psychological stress and… read more.
There appears to be no association between hormonal contraception and the prevalence of idiopathic intracranial hypertension, researchers reported on March 25, 2026 in Neurology, the medical journal of… read more.
When patients undergo general anesthesia, doctors can choose among several drugs. Although each of these drugs acts on neurons in different ways, they all lead to the same… read more.
Researchers report that people with type 1 diabetes are nearly three times as likely to develop dementia compared to those without type 1 diabetes. The findings appeared in… read more.
Youth football accounts for the largest share of sports‑related traumatic brain injuries (TBIs) in children and young adults, nearly one in every five TBIs, according to a preliminary… read more.
The EMA has recommended the refusal of the marketing authorisation for Daybue, intended for the treatment of Rett syndrome, a rare inherited condition that affects the brain and… read more.
NICE(UK): Cerliponase alfa is not recommended, within its marketing authorisation, for treating neuronal ceroid lipofuscinosis type 2 (CLN2; also known as tripeptidyl peptidase 1 deficiency). This recommendation is not intended… read more.
AbbVie announced that it has received marketing approval in Japan for Aquipta tablets (atogepant), a calcitonin gene-related peptide (CGRP) receptor antagonist, for the prevention of migraine attacks in… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
